ASX Announcement

15 June 2022

Presentation at the 2nd Annual Oligonucleotide for CNS Summit

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] is pleased to announce that the Company has been invited to present at the 2nd Annual Oligonucleotide for CNS Summit on 15th June 2022. Dr George Tachas, Director, Drug Discovery & Patents, will give the presentation in the program session "Uncovering the Clinical Research Propelling Oligonucleotide Therapeutic Development Forwards in 2022 & Beyond", 8.30am EDT.

Dr Tachas' presentation is entitled "*Learning How systemically Delivering Antisense Oligonucleotides Targeting CD49d RNA (ATL1102) Significantly Reduces New Active Brain Lesions in Patients with Relapse Remitting Multiple Sclerosis*". In his virtual presentation, Dr Tachas will review: (i) the pharmacodynamics of ATL1102 with a focus on its effects on circulating white blood cells, (ii) ATL1102 safety data and pharmacokinetics, (iii) the pharmacology of systemically delivered antisense oligonucleotides on inflammation in the brain and blood brain barrier considerations; and (iv) the clinical potential of "low dose" ATL1102 for diseases of the central nervous system (CNS) with an inflammatory component beyond MS.

The 2nd Annual Oligonucleotides for CNS Summit held in Boston, USA, will unite a multinational faculty of experts including from Eli Lilly, Roche, Biogen, Alnylam, Servier, Stoke Therapeutics and divulge insights in relation to oligonucleotide therapeutic development against Alzheimer's, Huntington's, Glioblastoma and more as industry turn their heads towards the CNS in a bid to capitalize on its strategic opportunity. For more information, please see the link below.

https://oligonucleotides-cns.com/

This announcement has been authorised for release by the CEO.

For more information please contact:

Antisense Therapeutics
Mark Diamond
Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries
Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

About ATL1102 ATL1102 is an antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). Antisense inhibition of VLA-4 expression has demonstrated activity in a number of animal models of inflammatory disease including asthma and MS with the MS animal data having been published in a peer reviewed scientific journal. ATL1102 was shown to be highly effective in reducing MS lesions in a Phase IIa clinical trial in patients with RR-MS. The ATL1102 Phase IIa clinical data has been published in the medical Journal ***Neurology*** (Limmroth, V. et al Neurology, 2014; 83(20): 1780-1788). ATL1102 is the only drug targeting CD49d in clinical development for DMD.